Sign in
Not yet recruitingNo phase

Measuring liver vein pressure with an ultrasound scope in people with cirrhosis

Tests ultrasound-guided pressure measurement to guide treatment in adults with liver cirrhosis.

Key facts

Who runs it
Hospital Universitario Virgen Macarena
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
Status
Not yet recruiting
People taking part
35 people, planned
Started
1 Nov 2024
Expected to end
1 Nov 2027
Type of study
Observational
Record updated
29 October 2024

Who can take part

The trial is looking for adults with advanced liver disease (cirrhosis) who need beta-blocker medicine (NSBBs) to prevent complications. Their liver blood pressure will be measured during an endoscopic ultrasound.

Age
18 Years to 85 Years
Sex
All
Disease stage
Advanced liver disease (cirrhosis) where treatment with NSBBs is needed to prevent first complications (primary prophylaxis).
Main reasons for not taking part
  • Advanced liver cancer (hepatocellular carcinoma) that cannot be treated with the aim of removing all of the disease
  • Pregnancy
  • Narrowing of the food pipe, or any reason an upper endoscopy cannot be done
  • INR > 1.5 or platelets < 50,000 µL
  • Fluid in the belly (ascites), or any reason NSBB treatment cannot be given
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Patients diagnosed with advanced liver disease with an indication for primary prophylaxis with NSBBs

Who cannot take part

  • Age < 18 years. 2. Advanced stage hepatocellular carcinoma not eligible for curative treatment. 3. Pregnancy. 4. Esophageal stenosis. 5. INR > 1.5. 6. Platelets < 50,000 µL. 7. Ascites. 8. Patients with any contraindication for performing an upper gastrointestinal endoscopy
  • Patients with contraindication to NSBB treatment. 10. Refusal to sign the informed consent form to participate in the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hepatic cirrhosis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The development of Clinical significant PH (CSPH) is a major driver of complications. PPG is the strongest predictor of decompensation . The shortcomings of GPVH measurements and invasiveness has resulted in an area of unmet clinical need. Non-selective beta-blockers (NSBB) have demonstrated efficacy in reducing PH. However, this requires a second invasive procedure, and there is high interindividual variability in the hemodynamic response to NSBB. EUS-guided GPP measurement emerges as a more accurate, accessible and less invasive technique to potentially predict chronic hemodynamic response. The aim of this project is to assess the safety and efficacy of EUS-derived GPP measurement (EUS-GPP) in patients diagnosed with cirrhosis, to assess the acute hemodynamic response through EUS-derived GPP to intravenous propranolol administration in order to determine the patients who would benefit from NSBB treatment in primary prophylaxis to prevent decompensation using a strategy guided by EUS-GPP measurement.

The group in the trial

  • All patients attending the hepatology clinic or hospitalized with a diagnosis of liver cirrhosis

    All patients attending outpatient clinics or hospitalized with a diagnosis of viral etiology or alcohol-related liver cirrhosis will be evaluated for the indication of primary prophylaxis with NSBB according to Baveno VII guidelines. The choice of NSBB type was mainly based on clinical parameters, regardless of the presence of an acute hemodynamic response. In patients who did not show signs of circulatory dysfunction or refractory ascites, carvedilol was preferred, as it has been shown to be more potent in decreasing portal pressure. Carvedilol was initiated at a dose of 6.25 mg/day and, if tolerated, was subsequently increased to a target dose of 12.5 mg/day. Higher doses of carvedilol were only used in cases of concomitant hypertension. For propranolol users, the dose was progressively increased until the heart rate decreased to approximately 55 beats per minute. In patients with significant ascites, a maximum dose of 80 mg/day of propranolol was administered.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
Plain-language title
Measuring liver vein pressure with an ultrasound scope in people with cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06664307, who can take part
Record updated
29 October 2024